The FDA may need some support from the biotech and drug sectors as the agency seeks to improve its processes for reviewing medical products, writes Luke Timmerman in this column. Timmerman breaks down five ways that the industry can take part in restoring public confidence in the agency, including showing support for an FDA budget increase and banning advisory panel members with conflicts of interest.

Full Story:

Related Summaries